NBP
NBP clinical trials: NovaBridge Biosciences
Every trial on ClinicalTrials.gov where NovaBridge Biosciences is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 12
- Trials linked
- 11
- As lead sponsor
- 1
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
NBP on the catalyst calendar · NBP registry changes
- Primary completion Mar 2030Sponsor estimatePhase 2NCT07432295Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)I-Mab Biopharma US Limited · Solid TumorRecruitingNBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT04900818Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsI-Mab Biopharma US Limited · Solid TumorRecruitingNBPLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 8, 2023ActualPhase 2NCT05001347A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid TumorsI-Mab Biopharma US Limited · Ovarian CancerCompletedNBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 10, 2023ActualPhase 1NCT03934814Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and LymphomaI-Mab Biopharma US Limited · Solid TumorCompletedNBPLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 7, 2022ActualPhase 2/Phase 3NCT04341116Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)I-Mab Biopharma US Limited · Coronavirus Disease 2019 COVID-19CompletedNBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT04869501Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic CancerI-Mab Biopharma US Limited · CancerNo longer availableNBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2024Sponsor estimatePhase 1NCT04947033A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid TumorsI-Mab Biopharma US Limited · Advanced Solid TumorUnknown statusNBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 21, 2022ActualPhase 1NCT04678921Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid TumorsI-Mab Biopharma US Limited · Solid TumorCompletedNBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT05511350Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001I-Mab Biopharma US Limited · Solid Tumor Metastatic Cancer Advanced CancerNo longer availableNBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2023Sponsor estimatePhase 1NCT04457856A Study of TJ003234 in Rheumatoid Arthritis PatientsI-Mab Biopharma US Limited · Rheumatoid ArthritisUnknown statusNBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 5, 2019ActualPhase 1NCT03794180Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult SubjectsI-Mab Biopharma US Limited · Healthy Adult SubjectsCompletedNBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 22, 2022ActualPhase 1NCT07187141Nasal Protollin in Early Symptomatic Alzheimer's DiseaseBrigham and Women's Hospital · Alzheimer Disease (AD)CompletedNBPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner